These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32974896)

  • 1. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Costa E; Tibalinda P; Sterzi E; Leufkens HMG; Makani J; Kaale E; Luzzatto L
    Am J Hematol; 2021 Jan; 96(1):E2-E5. PubMed ID: 32974896
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD; Charache S; Terrin ML; Barton FB; Ballas SK
    Am J Hematol; 2000 May; 64(1):26-31. PubMed ID: 10815784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.
    Wang WC; Oyeku SO; Luo Z; Boulet SL; Miller ST; Casella JF; Fish B; Thompson BW; Grosse SD;
    Pediatrics; 2013 Oct; 132(4):677-83. PubMed ID: 23999955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periodic erythroexchange is an effective strategy for high risk paediatric patients with sickle-cell disease.
    Masera N; Tavecchia L; Pozzi L; Riva F; Vimercati C; Calabria M; Ronzoni S; Masera G; Perseghin P
    Transfus Apher Sci; 2007 Dec; 37(3):241-7. PubMed ID: 18042436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S; Haywood C; Segal JB; Dover GJ
    Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
    Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M
    Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 9. Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
    Nnebe-Agumadu U; Adebayo IA; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28632. PubMed ID: 32743869
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxyurea in sickle cell disease.
    Burke SM
    MCN Am J Matern Child Nurs; 1996; 21(4):210. PubMed ID: 8754440
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
    Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
    Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sickle cell disease in the Democratic Republic of the Congo: what are the barriers to treatment using hydroxyurea?].
    Mukinayi BM; Cibeyibeyi GK; Tumba GD; Gulbis B
    Pan Afr Med J; 2021; 38():41. PubMed ID: 33854670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.
    Mathias JG; Nolan VG; Klesges LM; Badawy SM; Cooper WO; Hankins JS; Smeltzer MP
    JAMA Netw Open; 2021 Oct; 4(10):e2128971. PubMed ID: 34643722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea.
    Grace RF; Su H; Sena L; Poussaint TY; Heeney MM; Gutierrez A
    Am J Hematol; 2010 Feb; 85(2):135-7. PubMed ID: 20052745
    [No Abstract]   [Full Text] [Related]  

  • 15. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 16. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
    Ghafuri DL; Abdullahi SU; Dambatta AH; Galadanci J; Tabari MA; Bello-Manga H; Idris N; Inuwa H; Tijjani A; Suleiman AA; Jibir BW; Gambo S; Gambo AI; Khalifa Y; Haliru L; Abdulrasheed S; Zakari MA; Greene BC; Trevathan E; Jordan LC; Aliyu MH; Baumann AA; DeBaun MR
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e56-e61. PubMed ID: 34001783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.